The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Translational Research Program
The Leukemia & Lymphoma Society is the world's largest voluntary health agency dedicated to funding blood cancer research, education, and patient services. Its mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.
To advance these goals, the society's Translational Research Program was developed to encourage and provide early support for clinical research in leukemia, lymphoma, and myeloma focused on innovative approaches to treatment, diagnosis, and prevention. The program is designed to support new and innovative research that demonstrates high promise for translating basic biomedical knowledge to clinical application. Projects should be based on molecular, cellular, or integrated systems findings and be conceptually innovative.
- Required Letter of Intent: Sep. 29, 2017
- Full Application: Nov. 15, 2017
Applicants must hold an M.D., Ph.D., or equivalent degree, and work in domestic or foreign non-profit organizations, such as universities, colleges, hospitals or laboratories. Applications may involve multiple such institutions and the Applicant should have an independent research or academic position. Applicants need not be U.S. citizens, and there are no restrictions on Applicant age, race, gender or creed.
Applications from non-academic facilities, post doctoral positions and the National Institutes of Health are not eligible
Limited to a maximum of $200,000, which includes direct costs and a maximum overhead of $19,982 or 11.1 percent of direct costs per year for three years. Budget requests must be carefully justified and commensurate with the project's needs.